Korea Now Reimburses BeOne’s Tevimbra First-Line in Three Cancers, Using PD-L1 Cutoffs to Set the Limits
One reimbursement decision moved a second-line PD-1 into first line across three common cancers, inside biomarker limits.
South Korea
Korea Repriced 36 Fewer Items This Year and Took Out the Same ₩33.9 Billion
Thirty-six fewer items produced the same saving. Nothing about efficacy changed. The medicines that grew paid for it.
Korea’s Reimbursement Delay Is a Staffing Problem, and the Ministry Said So
An industry association found the public agrees with industry. The news came later, from a division director naming headcount as the bottleneck.
Korea adds Pergoveris pen to reimbursement rolls, vial already covered
This is a device listing, not an eligibility expansion. The indication is unchanged, and the criteria were relaxed back in April 2025.
Singapore Approved Both Blenrep Combinations. Korea Reimbursed Only the One With Survival Data.
Same drug, same week, two Asian markets. The regulator approved on progression-free survival. The payer funded only the regimen with overall survival data.
A KAIST Barrier Chip Separated Three Glioblastoma Patients That MGMT Testing Called Identical
Three glioblastoma patients returned identical MGMT results and behaved differently on a barrier chip. The sample size is three, and the framing still matters.
Korea Cleared Two Diagnostics on One Day, and Both Remove a Specialist
Nobody gained insurance access. Designation is the gate before the negotiation. The real story is that both lead technologies remove a specialist.